Important Safety Information | Prescribing Information


Bausch + Lomb continually works with eye care professionals to provide valuable
savings to eligible patients on their prescriptions. We offer various access programs to help
eligible patients receive affordable access to Bausch + Lomb eye care products.





Most eligible commercially insured patients PAY NO MORE THAN $35* co-pay for 1st prescription and eligible refills. Exclusively at Walgreens and other participating independent pharmacies.

Discounted pricing is also available for eligible uninsured patients.*

Most eligible patients PAY NO MORE THAN $60 on each PROLENSA prescription.

To help your eligible Medicare patients save on PROLENSA, instruct them to follow 3 easy steps:


To activate the print coupon, call
1-855-280-0580. To activate the
online download coupon and review eligibility
criteria, visit and follow the instructions.

Size: 3 mL
Commercially insured: $35*
Eligible Uninsured: $60*
Eligible fills: 6

To activate the print coupon, call
1-800-706-5160. To activate the online download coupon, agree to the statements on

Redeem the coupon card at a participating retail pharmacy with prescription and insurance card.

Sign and mail the prewritten letter to health plan. Health care plan address can be found on your Medicare provider card.

*Terms and conditions apply. Please visit for eligibility criteria and terms and conditions.


Bausch + Lomb has aligned with Walgreens to
stock product and help eligible patients redeem
prescription savings on our products.

Contact your sales representative to provide in-office printed coupons.

If you have any questions regarding your
eligibility or benefits, please call 1-855-280-0580.

†Terms and conditions apply. Offer varies at cash-only pharmacies. Please visit for eligibility criteria.


Contact your sales representative to provide in-office printed coupons. 

If you have questions related to this program, please call 1-800-706-5160.


Access additional resources on PROLENSA ››   


PROLENSA (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.


  • PROLENSA contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.

  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

  • PROLENSA should not be instilled while wearing contact lenses. The preservative in PROLENSA, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.

  • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Please click here for Prescribing Information about PROLENSA.
Please click here for references.